Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Splenic Cyst Following Abdominal Trauma?

Schalk E, Fischer T, Wolleschak D.

Dtsch Arztebl Int. 2019 May 17;116(20):362. doi: 10.3238/arztebl.2019.0362b. No abstract available.

2.

SDF1α-induced chemotaxis of JAK2-V617F-positive cells is dependent on Bruton tyrosine kinase and its downstream targets PI3K/AKT, PLCγ1 and RhoA.

Nimmagadda SC, Frey S, Müller P, Wolleschak D, Weinert S, Keller U, Edelmann B, Fischer T.

Haematologica. 2019 Jul;104(7):e288-e292. doi: 10.3324/haematol.2018.201921. Epub 2019 Feb 14. No abstract available.

3.

JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation.

Edelmann B, Gupta N, Schnoeder TM, Oelschlegel AM, Shahzad K, Goldschmidt J, Philipsen L, Weinert S, Ghosh A, Saalfeld FC, Nimmagadda SC, Müller P, Braun-Dullaeus R, Mohr J, Wolleschak D, Kliche S, Amthauer H, Heidel FH, Schraven B, Isermann B, Müller AJ, Fischer T.

J Clin Invest. 2018 Oct 1;128(10):4359-4371. doi: 10.1172/JCI90312. Epub 2018 Jul 19.

4.

The cell fate determinant Scribble is required for maintenance of hematopoietic stem cell function.

Mohr J, Dash BP, Schnoeder TM, Wolleschak D, Herzog C, Tubio Santamaria N, Weinert S, Godavarthy S, Zanetti C, Naumann M, Hartleben B, Huber TB, Krause DS, Kähne T, Bullinger L, Heidel FH.

Leukemia. 2018 May;32(5):1211-1221. doi: 10.1038/s41375-018-0025-0. Epub 2018 Jan 30.

PMID:
29467485
5.

Mitochondrial BAX Determines the Predisposition to Apoptosis in Human AML.

Reichenbach F, Wiedenmann C, Schalk E, Becker D, Funk K, Scholz-Kreisel P, Todt F, Wolleschak D, Döhner K, Marquardt JU, Heidel F, Edlich F.

Clin Cancer Res. 2017 Aug 15;23(16):4805-4816. doi: 10.1158/1078-0432.CCR-16-1941. Epub 2017 Apr 18.

6.

Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN.

Schnöder TM, Eberhardt J, Koehler M, Bierhoff HB, Weinert S, Pandey AD, Nimmagadda SC, Wolleschak D, Jöhrens K, Fischer T, Heidel FH.

J Cancer Res Clin Oncol. 2017 May;143(5):807-820. doi: 10.1007/s00432-017-2354-1. Epub 2017 Feb 23.

PMID:
28233092
7.

JAK2-V617F activates β1-integrin-mediated adhesion of granulocytes to vascular cell adhesion molecule 1.

Gupta N, Edelmann B, Schnoeder TM, Saalfeld FC, Wolleschak D, Kliche S, Schraven B, Heidel FH, Fischer T.

Leukemia. 2017 May;31(5):1223-1226. doi: 10.1038/leu.2017.26. Epub 2017 Jan 18. No abstract available.

8.

Chronic myelogenous leukemia evolving after treatment of multiple myeloma.

Wolleschak D, Heidel FH.

Blood. 2016 Jul 7;128(1):146. doi: 10.1182/blood-2016-03-706945. No abstract available.

9.

Gain of function in Jak2V617F-positive T-cells.

Nishanth G, Wolleschak D, Fahldieck C, Fischer T, Mullally A, Perner F, Schnöder TM, Just S, Heidel FH, Schlüter D.

Leukemia. 2017 Apr;31(4):1000-1003. doi: 10.1038/leu.2017.6. Epub 2017 Jan 11. No abstract available.

PMID:
28074070
10.

Characteristics and treatment of polycythemia vera patients in clinical practice: a multicenter chart review on 1476 individuals in Germany.

Jentsch-Ullrich K, Eberhardt J, Zeremski V, Koehler M, Wolleschak D, Heidel FH.

J Cancer Res Clin Oncol. 2016 Sep;142(9):2041-9. doi: 10.1007/s00432-016-2209-1. Epub 2016 Jul 18.

PMID:
27431664
11.

Expression and function of ABC-transporter protein ABCB1 correlates with inhibitory capacity of Ruxolitinib in vitro and in vivo.

Ebert C, Perner F, Wolleschak D, Schnöder TM, Fischer T, Heidel FH.

Haematologica. 2016 Mar;101(3):e81-5. doi: 10.3324/haematol.2015.136754. Epub 2015 Nov 20. No abstract available.

12.

Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function.

Perner F, Schnöder TM, Ranjan S, Wolleschak D, Ebert C, Pils MC, Frey S, Polanetzki A, Fahldieck C, Schönborn U, Schraven B, Isermann B, Fischer T, Heidel FH.

Leukemia. 2016 Apr;30(4):991-5. doi: 10.1038/leu.2015.218. Epub 2015 Aug 5. No abstract available.

PMID:
26242463
13.

A rare cause of lower back pain.

Wolleschak D, Heidel FH.

Blood. 2014 Jul 10;124(2):165. No abstract available.

14.

Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function.

Wolleschak D, Mack TS, Perner F, Frey S, Schnöder TM, Wagner MC, Höding C, Pils MC, Parkner A, Kliche S, Schraven B, Hebel K, Brunner-Weinzierl M, Ranjan S, Isermann B, Lipka DB, Fischer T, Heidel FH.

Haematologica. 2014 Jun;99(6):e90-3. doi: 10.3324/haematol.2014.104331. Epub 2014 Mar 14. No abstract available.

15.

Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature.

Wolleschak D, Schalk E, Krogel C, Schnoeder TM, Luehr H, Jentsch-Ullrich K, Fischer T, Heidel FH.

J Hematol Oncol. 2013 Jun 11;6:39. doi: 10.1186/1756-8722-6-39. Review.

Supplemental Content

Loading ...
Support Center